First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares; Tudor-Eliade Ciuleanu; Manuel Cobo; Michael Schenker; Bogdan Zurawski; Juliana Menezes; Eduardo Richardet; Jaafar Bennouna; Enriqueta Felip; Oscar Juan-Vidal; Aurelia Alexandru; Hiroshi Sakai; Alejo Lingua; Pamela Salman; Pierre-Jean Souquet; Pedro De Marchi; Claudio Martin; Maurice Pérol; Arnaud Scherpereel; Shun Lu; Thomas John; David P Carbone; Stephanie Meadows-Shropshire; Shruti Agrawal; Abderrahim Oukessou; Jinchun Yan; Martin Reck

doi:10.1016/s1470-2045(20)30641-0

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.09.010 ◽

2021 ◽

Author(s):

Luis G. Paz-Ares ◽

Suresh S. Ramalingam ◽

Tudor-Eliade Ciuleanu ◽

Jong-Seok Lee ◽

Laszlo Urban ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(17)30123-x ◽

2017 ◽

Vol 389 (10072) ◽

pp. 917-929 ◽

Cited By ~ 425

Author(s):

Jean-Charles Soria ◽

Daniel S W Tan ◽

Rita Chiari ◽

Yi-Long Wu ◽

Luis Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Platinum Based Chemotherapy ◽

Open Label Phase

Download Full-text

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00134-x ◽

2021 ◽

Author(s):

Jianxing He ◽

Chunxia Su ◽

Wenhua Liang ◽

Shidong Xu ◽

Lin Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adjuvant Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Egfr Mutant

Download Full-text

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)

10.1158/1538-7445.am2021-ct041 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Lin Wu ◽

Xinmin Yu ◽

Yan Wang ◽

Puyuan Xing ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30318-2 ◽

2017 ◽

Vol 18 (8) ◽

pp. 1116-1125 ◽

Cited By ~ 144

Author(s):

Corinne Faivre-Finn ◽

Michael Snee ◽

Linda Ashcroft ◽

Wiebke Appel ◽

Fabrice Barlesi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Open Label Phase ◽

Superiority Trial

Download Full-text

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)02098-5 ◽

2021 ◽

Author(s):

Enriqueta Felip ◽

Nasser Altorki ◽

Caicun Zhou ◽

Tibor Csőszi ◽

Ihor Vynnychenko ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Chemotherapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Resected Stage

Download Full-text

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial

The Lancet Healthy Longevity ◽

10.1016/s2666-7568(21)00255-5 ◽

2021 ◽

Vol 2 (12) ◽

pp. e791-e800 ◽

Cited By ~ 1

Author(s):

Yoshihito Kogure ◽

Shunichiro Iwasawa ◽

Hideo Saka ◽

Yoichiro Hamamoto ◽

Akiko Kada ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Older Patients ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdx091.064 ◽

2017 ◽

Vol 28 ◽

pp. ii50-ii51 ◽

Cited By ~ 4

Author(s):

L. Paz-Ares ◽

J. Brahmer ◽

M.D. Hellmann ◽

M. Reck ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text